Insilico Medicine, a Hong Kong-listed AI drug discovery company, has entered a partnership with South Korea’s SK Biopharmaceuticals in a deal valued at over $2.5 billion. The agreement, announced this week, focuses on developing new neuroimmune therapies using Insilico’s Pharma.AI platform. Insilico will receive $18 million in near-term payments, with the potential to earn up to $2.5 billion through development milestones and royalties, according to fortune.com.
Under the deal, Insilico will design drug candidates targeting neuroimmune conditions, while SK Biopharmaceuticals will lead late-stage development and commercialization efforts. This collaboration marks Insilico’s largest partnership with an Asia-Pacific firm and its second major deal with a global pharmaceutical company. Earlier this year, Insilico signed a $2.75 billion agreement with U.S.-based Eli Lilly to develop novel oral therapeutics. Alex Zhavoronkov, Insilico’s co-CEO, described the company’s ambition to transform pharmaceutical innovation, likening it to SpaceX’s impact on aerospace, as reported by fortune.com.
The deal highlights growing interest in AI-driven drug discovery, a sector attracting significant investments amid rising demand for innovative treatments. Insilico’s partnerships with SK Biopharmaceuticals and Eli Lilly position it among leading firms leveraging artificial intelligence to accelerate pharmaceutical R&D. The $2.5 billion valuation reflects confidence in AI platforms to streamline drug candidate design and reduce development timelines, aligning with broader trends in biotech and pharma collaborations, according to fortune.com.
Following the announcement, Insilico Medicine’s shares surged 5.6% in Hong Kong trading. The company’s next milestone will be advancing candidate drugs into clinical development stages under the SK Biopharmaceuticals partnership, with milestone payments and royalties contingent on successful progress, as detailed by fortune.com.